Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care
about
Cryptococcal meningitis treatment strategies in resource-limited settings: a cost-effectiveness analysisReconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcLMultisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrastLATERAL FLOW ASSAY FOR CRYPTOCOCCAL ANTIGEN: AN IMPORTANT ADVANCE TO IMPROVE THE CONTINUUM OF HIV CARE AND REDUCE CRYPTOCOCCAL MENINGITIS-RELATED MORTALITYCryptococcus gattii infectionsA screen-and-treat strategy targeting visceral leishmaniasis in HIV-infected individuals in endemic East African countries: the way forward?A Zebrafish Model of Cryptococcal Infection Reveals Roles for Macrophages, Endothelial Cells, and Neutrophils in the Establishment and Control of Sustained Fungemia.Cryptococcal meningitis: epidemiology and therapeutic options.Unmasking cryptococcal meningitis immune reconstitution inflammatory syndrome in pregnancy induced by HIV antiretroviral therapy with postpartum paradoxical exacerbation.Neurocognitive function in HIV-infected persons with asymptomatic cryptococcal antigenemia: a comparison of three prospective cohortsPrevalence of cryptococcal infection among advanced HIV patients in Argentina using lateral flow immunoassay.Point-of-care lateral flow assays for tuberculosis and cryptococcal antigenuria predict death in HIV infected adults in UgandaPerformance of cryptococcal antigen lateral flow assay using saliva in Ugandans with CD4 <100.Utility of urine and serum lateral flow assays to determine the prevalence and predictors of cryptococcal antigenemia in HIV-positive outpatients beginning antiretroviral therapy in Mwanza, TanzaniaUpdate on opportunistic infections in the era of effective antiretroviral therapyClinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory.Long term 5-year survival of persons with cryptococcal meningitis or asymptomatic subclinical antigenemia in Uganda.Methods of rapid diagnosis for the etiology of meningitis in adultsHigh prevalence of Cryptococcal antigenemia among HIV-infected patients receiving antiretroviral therapy in Ethiopia.Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program--Vietnam.Prevalence, correlates, and outcomes of cryptococcal antigen positivity among patients with AIDS, United States, 1986-2012.Pitfalls in Serological Diagnosis of Cryptococcus gattii Infections.Cryptococcal Antigenemia in Immunocompromised Human Immunodeficiency Virus Patients in Rural Tanzania: A Preventable Cause of Early Mortality.Cryptococcal Meningitis: Diagnosis and Management Update.Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa.Six-month outcomes of HIV-infected patients given short-course fluconazole therapy for asymptomatic cryptococcal antigenemia.Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda.Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda.Brief Report: Effects of Tenofovir and Amphotericin B Deoxycholate Coadministration on Kidney Function in Patients Treated for Cryptococcal MeningitisTowards a scalable HIV cure research agenda: the role of co-infections.HIV infection and immune activation: the role of coinfections.Evolution of Cryptococcal Antigen Testing: What is new?Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study.Strategies to reduce mortality and morbidity due to AIDS-related cryptococcal meningitis in Latin AmericaNew Insights into HIV/AIDS-Associated Cryptococcosis.Comparison of cryptococcal antigenemia between antiretroviral naïve and antiretroviral experienced HIV positive patients at two hospitals in Ethiopia.Asymptomatic cryptococcemia in resource-limited settings.Diagnosis of Cryptococcosis and Prevention of Cryptococcal Meningitis Using a Novel Point-of-Care Lateral Flow Assay.Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realizedNo association of cryptococcal antigenemia with poor outcomes among antiretroviral therapy-experienced HIV-infected patients in Addis Ababa, Ethiopia.
P2860
Q21144604-3A8C5EDB-D153-40DF-8A29-A097A7FDBF64Q24610164-610465A7-89D6-46AE-BC2B-A0FC9A47A7F7Q24620256-73337CD8-F569-4DDA-9E1E-72E7DE6C0299Q26783210-E0DC15C6-BA6C-44CF-A17A-E8726EC87257Q27002687-A52D82C9-5215-433D-8239-83E3A5353CAFQ28541690-36541E83-1C96-45E5-924B-165470E337E5Q30815458-5B5E712F-13DF-4679-8808-8B1F28C1DB2EQ33633343-B6E1E648-A0D4-4766-9621-63D9001E9331Q33765829-9F571B96-FE6B-4DA1-A6E3-BD84FAD34B1DQ33792332-84A555B0-3DBF-4B7D-96A0-7A15CD20C841Q33803185-1B2DD192-87D1-443C-BFFC-DC197C782F44Q33855961-9185737D-85AA-422F-8865-8BFC8D331D7DQ33982206-BA3BA3AF-B532-478F-9F90-11E571D27DC0Q34024241-F71BFAFC-7C5C-4FFE-B410-7942F72B011FQ34085853-017F07F2-DE84-4684-B603-71E035E1A7D7Q34482498-D69D3981-15D1-4E26-B7E9-0653093648ABQ34516367-303C4535-B85D-4CB7-AFF0-9C331B11F760Q34554521-9F3F6FDC-CFF9-409F-8471-B02DD8667502Q34613471-C4A44753-3ECB-4E42-9F54-3D56AC991B0BQ34692926-1674022A-BC43-4CF5-A050-D9E8885C06B0Q35171867-55C66749-AA8E-4051-B4DB-B34C9D2C772FQ35763934-7B180EC0-B097-4411-8FC5-DF6D34A1A164Q35880502-AC9A667A-58A3-40C7-8304-6BD51986F607Q35951094-043F378E-7CC9-4AB2-B9D1-CE6B766AA7E8Q36271651-CDCD152C-ABF7-4D9B-AD38-B48FF9411C19Q36277675-CB8BC6F6-DB0E-45CA-A62D-CE9826ACBD84Q36290696-1B781565-B6D8-431C-92A0-38D06ED3776FQ36321037-91BD2197-E30C-41F6-B541-B7E56DF91DAEQ36463811-814EF687-01AD-419E-8D1B-F1354E04FEA6Q36540033-F7804A5C-133C-440D-8002-0C63C79EA9B9Q36796783-6215E2CD-3478-4BDD-AB6F-F250A024B5E2Q36873953-4A866588-C3B7-4B2D-96C0-A345BD500879Q37052988-964E8F96-189E-4C19-9BD3-61B07F48066FQ37105884-8696D7AF-B577-4139-B87E-36B648F0A968Q37156556-70A79559-D548-4E6E-87BC-D4F68E949609Q37215923-36A07EE1-694E-45ED-814B-97E1B560A107Q37259640-8BC070F4-8075-454C-AD52-EADFEAE4DB73Q37351578-6719C063-4558-4235-BCD0-81AB442B6C8FQ37393668-182034D6-EBA7-4161-9DA1-EA196063BF13Q37499521-CC516243-1B43-494D-BA35-F9B8AA026528
P2860
Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Integrating cryptococcal antig ...... reatment into routine HIV care
@ast
Integrating cryptococcal antig ...... reatment into routine HIV care
@en
Integrating cryptococcal antig ...... reatment into routine HIV care
@nl
type
label
Integrating cryptococcal antig ...... reatment into routine HIV care
@ast
Integrating cryptococcal antig ...... reatment into routine HIV care
@en
Integrating cryptococcal antig ...... reatment into routine HIV care
@nl
prefLabel
Integrating cryptococcal antig ...... reatment into routine HIV care
@ast
Integrating cryptococcal antig ...... reatment into routine HIV care
@en
Integrating cryptococcal antig ...... reatment into routine HIV care
@nl
P2860
P3181
P1476
Integrating cryptococcal antig ...... reatment into routine HIV care
@en
P2093
Radha Rajasingham
P2860
P304
P3181
P356
10.1097/QAI.0B013E31824C837E
P407
P577
2012-04-15T00:00:00Z